Lidbree

Lidocaine, the active ingredient in Lidbree, is a local anesthetic presented as a sterile intrauterine formulation for use during gynecological procedures. It temporarily blocks nerve impulse transmission in the uterine tissue, providing rapid and reversible loss of sensation for diagnostic or therapeutic interventions.

GNH USA supplies Lidbree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides comprehensive documentation for import and clinical use.

Lidbree (lidocaine) is employed as a local anesthetic for intrauterine procedures, providing analgesia during gynecological interventions. - Hysteroscopic surgery: provides rapid mucosal anesthesia to facilitate instrument insertion and reduce patient discomfort. - Endometrial biopsy: numbs the uterine lining to allow tissue sampling with minimal pain. - Uterine curettage: induces local anesthesia to enable safe removal of uterine contents.

Lidocaine administered intrauterinely may be associated with both frequent and infrequent adverse reactions.

Common Side Effects: - Mild uterine cramping: transient pain or spasm during or after administration. - Vaginal irritation: burning or itching at the application site. - Nausea: occasional feeling of queasiness. - Dizziness or light‑headedness: brief episodes of vertigo.

Serious or Rare Side Effects: - Allergic reaction: rash, swelling, or anaphylaxis requiring immediate medical attention. - Cardiovascular toxicity: hypotension, arrhythmias, or cardiac arrest in cases of systemic absorption. - Central nervous system effects: seizures, tremors, or loss of consciousness.

When using Lidbree, several safety considerations should be observed to minimize risk. - Allergy assessment: verify no known hypersensitivity to lidocaine or related amide anesthetics. - Dose limitation: use the lowest effective volume to achieve adequate anesthesia. - Cardiovascular monitoring: observe heart rate and blood pressure during and after administration. - Liver function: exercise caution in patients with severe hepatic impairment due to reduced metabolism. - Pregnancy and lactation: consider potential fetal exposure; use only if benefits outweigh risks. - Store at room temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Lidbree may interact with other medicines, altering its safety profile or efficacy.

Major Interactions (Avoid): - Other local anesthetics: concurrent use can increase risk of systemic toxicity. - Class I antiarrhythmic agents (e.g., quinidine, procainamide): may potentiate cardiac conduction disturbances. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise lidocaine plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Beta‑blockers (e.g., propranolol): may enhance lidocaine’s bradycardic effects. - Calcium channel blockers (e.g., verapamil): may affect cardiac conduction when combined. - Monoamine oxidase inhibitors: may increase risk of CNS side effects. - Diuretics (e.g., furosemide): may reduce plasma protein binding, modestly raising free lidocaine.